Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer

M. O. Nicoletto, R. Padrini, H. Koussis, A. Rosabian, S. Aversa, L. Endrizzi, P. Azzoni, M. Palumbo, M. V. Fiorentino

Research output: Contribution to journalArticlepeer-review


Mitoxantrone has shown moderate activity in advanced epithelial ovarian cancer following intermittent i.v. administration. Experiments and clinical data suggest that long-term continuous drug infusion may achieve a better therapeutic result with less toxicity. This hypothesis was tested in patients with advanced ovarian cancer who had been pretreated with other agents. Mitoxantrone was infused continuously in 21-day courses beginning every 6 weeks. If severe toxicity did not occur, the infusion rate was increased by 0.1-0.2 mg/m2 per day. The mitoxantrone solution proved to be stable over the 21-day infusion period. For ethical reasons an optimal two-stage design was employed. The trial was interrupted at the end of the first recruitment stage because the target of 3 responses out of 13 patients had not been achieved (only 1 patient had a partial response). Hematologic toxicity was observed in 11 patients, and 2 of them had a catheter occlusion. In conclusion, we found that 21-day of infusion of mitoxantrone apparently has no clinical benefit as compared with bolus administration in patients with advanced ovarian cancer.

Original languageEnglish
Pages (from-to)506-510
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Issue number6
Publication statusPublished - Nov 1995


  • Advanced epithelial ovarian cancer
  • Mitoxantrone infusion
  • Mitoxantrone stability

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this